Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy

A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastatic breast cancer patients are refractory to Her2-targeted trastuzumab-like therapy. Some of this resistance has been attributed to the upregulation of immune checkpoints such as programmed cell death-1...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Main Authors: Mittal, Deepak, Vijayan, Dipti, Neijssen, Joost, Kreijtz, Joost, Habraken, Maurice M. J. M., Van Eenennaam, Hans, Van Elsas, Andrea, Smyth, Mark J.
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2019
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6791437/
https://ncbi.nlm.nih.gov/pubmed/31646095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1648171
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares